CytRx Corporation (CYTR): Hedge Funds Are Snapping Up

Is CytRx Corporation (NASDAQ:CYTR) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. It’s not surprising given that hedge funds have access to better information and more resources to find the latest market-moving information.

CytRx Corporation (NASDAQ:CYTR) has experienced an increase in hedge fund interest of late. At the end of this article we will also compare CYTR to other stocks, including Skullcandy Inc (NASDAQ:SKUL), GulfMark Offshore, Inc. (NYSE:GLF), and ROI Acquisition Corp (NASDAQ:ROIQ) to get a better sense of its popularity.

If you’d ask most investors, hedge funds are viewed as slow, outdated investment tools of the past. While there are over 8000 funds with their doors open at the moment, We look at the top tier of this club, approximately 700 funds. These money managers have their hands on the majority of the smart money’s total asset base, and by shadowing their inimitable picks, Insider Monkey has spotted a few investment strategies that have historically surpassed the market. Insider Monkey’s small-cap hedge fund strategy outstripped the S&P 500 index by 12 percentage points per year for a decade in their back tests.

Keeping this in mind, let’s take a peek at the fresh action surrounding CytRx Corporation (NASDAQ:CYTR).

How are hedge funds trading CytRx Corporation (NASDAQ:CYTR)?

At the Q3’s end, a total of 7 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 40% from one quarter earlier. With the smart money’s capital changing hands, there exists a few notable hedge fund managers who were boosting their holdings substantially (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, QVT Financial, managed by Daniel Gold, holds the number one position in CytRx Corporation (NASDAQ:CYTR). QVT Financial has a $13 million position in the stock, comprising 0.4% of its 13F portfolio. The second largest stake is held by James A. Silverman of Opaleye Management, with a $3.6 million position; the fund has 1.8% of its 13F portfolio invested in the stock. The remaining members of the smart money that are bullish comprise Julian Baker and Felix Baker’s Baker Bros. Advisors and Nathan Fischel’s DAFNA Capital Management.